COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements

Featured Journal Content

 

COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

 

AstraZeneca
Press Releases – No new digest announcements identified

Bharat Biotech
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias
Vacunas cubanas muestran altos títulos de neutralización contra ómicron.
Resumen:  Las vacunas cubanas han permitido que la COVID-19 en Cuba s comporte de modo diferente al resto del mundo. Las últimas evidencias demuestran altos títulos de neutralización contra la variante ómicron.
28 de Enero, 2022
[Cuban vaccines show high neutralization titers against omicron.
Abstract: Cuban vaccines have allowed COVID-19 in Cuba to behave differently from the rest of the world. The latest evidence shows high neutralization titers against the omicron variant.]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News
January 17, 2022
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases – No new digest announcements identified

 

Moderna
Press Releases
January 27, 2022
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology

January 26, 2022
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant

 

Novavax
Press Releases
Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine
Jan 28, 2022

 

Pfizer
Recent Press Releases
01.27.2022
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment

01.25.2022
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

01.24.2022
Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media – No new digest announcements identified

 

Merck
News releases
January 28, 2022
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

 

Novartis
News
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Jan 10, 2022

 

SK Biosciences
Press releases – No new digest announcements identified

 

Valneva
Press Releases
January 25, 2022
Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine Candidate